Clinedge

1. Biogen, Inc. $1,381,500 14 payments
2. AstraZeneca Pharmaceuticals LP $237,507 11 payments
3. Welch Allyn $217,152 12 payments
4. Pfizer Inc. $196,746 22 payments
5. GlaxoSmithKline, LLC. $195,324 35 payments
6. E.R. Squibb & Sons, L.L.C. $46,132 6 payments
7. Boehringer Ingelheim Pharmaceuticals, Inc. $37,852 3 payments
8. AbbVie, Inc. $32,393 6 payments
9. Boehringer Ingelheim Canada Ltd.Ltee $24,244 33 payments
10. Celgene Corporation $15,000 3 payments

1. A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 $640,575 2 payments
2. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $423,983 2 payments
3. AutoDx-DR Prospective Clinical Validation Study Protocol $217,152 12 payments
4. A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $196,746 22 payments
5. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $181,175 2 payments
6. A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou $134,065 27 payments
7. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $121,798 6 payments
8. A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) $115,709 5 payments
9. Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease $63,165 1 payment
10. Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis $38,544 1 payment

1. Other $217,152 12 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.